# PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Source: https://onco.cc/trials/nct06673017/  
OnCo record `nct06673017` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of PTM-101 run by PanTher Therapeutics, now recruiting.

## Summary

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) is a phase 1 interventional study registered as NCT06673017 by PanTher Therapeutics, with 26 participants planned, started 2025-04-14. Conditions recorded: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma and Pancreatic Cancer. Interventions recorded: PTM-101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06673017
- Phase: 1
- Setting: A Phase Ib Dose Escalation/Dose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
- Sponsor: PanTher Therapeutics
- Enrolled: 26

## Sources

- ClinicalTrials.gov NCT06673017: https://clinicaltrials.gov/study/NCT06673017

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [PTM-101](https://onco.cc/drugs/ptm-101/)
- companies: [PanTher Therapeutics](https://onco.cc/companies/panther-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06673017.json